Frankfurt - Delayed Quote EUR

Corvus Pharmaceuticals, Inc. (C17.F)

4.7600

+0.0150

+(0.32%)

As of January 30 at 8:12:27 AM GMT+1. Market Open.

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placeboBURLINGAME, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data, which include

GlobeNewswire 17 days ago

CRVS
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, which is being held in San Francisco from January 13-16, 2025. The Company’s presentation will be on Wednesday, January 15 at 2:15 pm ET

GlobeNewswire 23 days ago

CRVS
We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Corvus...

Simply Wall St. 23 days ago

CRVS
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy. These doses were selected based on the company’s prior experience evaluating soquelitinib in T-cell lymphoma patients. The company is reporting complete results from Cohort 1 of the trial, which inc

Benzinga last month

CRVS
Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell

Corvus Pharmaceuticals (CRVS) said Wednesday that interim results from a phase 1 trial of its experi

PREMIUM
MT Newswires last month

CRVS
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million Company to host conference call and webcast today at 8:00 a.m. ET / 5:00 a.m. PT BURLINGAME, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical compan

GlobeNewswire last month

CRVS
Tessera gets sickle cell funding; Corvus shares slide on eczema data

The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara agreed to a reverse merger and J&J had a drug application rejected.

BioPharma Dive last month

JNJ

CRVS

SRPT
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press rel

GlobeNewswire last month

CRVS
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%

Key Insights The considerable ownership by individual investors in Corvus Pharmaceuticals indicates that they...

Simply Wall St. last month

CRVS
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journalBURLINGAME, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, as a novel approach to modulate tumor immunity. The data was published in npj Drug Discovery (part of the Nature portfolio of journals), an o

GlobeNewswire last month

CRVS
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases Data will be presented in a poster at ACR Convergence 2024, the annual meeting of the American College of Rheumatology BURLINGAME, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data highlighting the potential of soquelitinib, the C

GlobeNewswire 2 months ago

CRVS
An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% Undervalued

Key Insights Corvus Pharmaceuticals' estimated fair value is US$15.07 based on 2 Stage Free Cash Flow to Equity Corvus...

Simply Wall St. 2 months ago

CRVS
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ...

Corvus Pharmaceuticals Inc (CRVS) progresses with promising trials and designations, despite reporting a significant net loss for the quarter.

GuruFocus.com 2 months ago

CRVS
Corvus: Q3 Earnings Snapshot

BURLINGAME, Calif. AP) — Corvus Pharmaceuticals Inc. CRVS) on Tuesday reported a loss of $40.2 million in its third quarter.

Associated Press Finance 2 months ago

CRVS
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-st

GlobeNewswire 2 months ago

CRVS
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstractBURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company’s adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in the treatment of metastatic castration resista

GlobeNewswire 2 months ago

CRVS
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 12, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-

GlobeNewswire 2 months ago

CRVS
Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment

Last week, Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) insiders, who had purchased shares in the previous 12 months...

Simply Wall St. 3 months ago

CRVS
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.

Zacks 4 months ago

CRVS
$Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma$

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical

GlobeNewswire 4 months ago

CRVS

Performance Overview

Return	C17.F	S&P 500
YTD	-2.06%	+2.78%
1-Year	+160.11%	+23.20%
3-Year	+242.45%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Corvus Pharmaceuticals, Inc. (C17.F)

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Tessera gets sickle cell funding; Corvus shares slide on eczema data

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% Undervalued

Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ...

Corvus: Q3 Earnings Snapshot

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Performance Overview